Bettina Altmann

Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial

Viola Poeschel, Gerhard Held, Marita Ziepert et al. · The Lancet · 2019 · 244 citations · Full text

Vitamin D Deficiency Impairs Rituximab-Mediated Cellular Cytotoxicity and Outcome of Patients With Diffuse Large B-Cell Lymphoma Treated With but Not Without Rituximab

Joerg Thomas Bittenbring, Frank Neumann, Bettina Altmann et al. · Journal of Clinical Oncology · 2014 · 132 citations · Full text

A randomized phase 3 trial of auto vs. allo transplantation as part of first-line therapy in poor-risk peripheral T-NHL

Norbert Schmitz, Lorenz Truemper, Krimo Bouabdallah et al. · Blood · 2020 · 67 citations · Full text

USP9X stabilizes XIAP to regulate mitotic cell death and chemoresistance in aggressive B‐cell lymphoma

Katharina Engel, Martina Rudelius, Jolanta Slawska et al. · EMBO Molecular Medicine · 2016 · 65 citations · Full text

Radiotherapy (RT) to bulky (B) and extralymphatic (E) disease in combination with 6xR-CHOP-14 or R-CHOP-21 in young good-prognosis DLBCL patients: Results of the 2x2 randomized UNFOLDER trial of the DSHNHL/GLA.

Michael Pfreundschuh, Niels Murawski, Marita Ziepert et al. · Journal of Clinical Oncology · 2018 · 49 citations

Cancer Management, Pathology, Pharmacotherapy +20